SymBio Signs Worldwide Exclusive License Agreement with Chimerix to Develop and Commercialize Brincidofovir


  • Chimerix to receive $5M up front, up to $150M as clinical, regulatory & commercial milestone with royalties on global sales of Brincidofovir. SymBio to get exclusive WW rights to develop, manufacture & commercialize Brincidofovir in all human indications excluding prevention and treatment of smallpox and is responsible for all development, manufacturing & commercialization activities
  • The collaboration will allow Chimerix to focus on the development of Dociparstat sodium (CX-01) in a P-III study as a 1L treatment for AML and provide an opportunity to participate in the value of ongoing development of Brincidofovir through milestones & royalties
  • Chimerix’s Brincidofovir (BCV, CMX001) is an anti-viral therapy being developed for the treatment of cytomegalovirus, adenovirus, smallpox, and ebolavirus infections and is a prodrug of cidofovir

Click here to­ read full press release/ article | Ref: Chimerix | Image: Pappas Capital